Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


STADA Arzneimittel AG

Latest From STADA Arzneimittel AG

Stada’s Owners Hold ‘Initial Exploratory Talks’ For Potential Sale

For the first time, privately-owned Stada has acknowledged the potential for a sale of the business – six years after the private equity duo Bain Capital and Cinven announced a deal worth upwards of €5.4bn for the German firm.

Deals M & A

Xbrane And Stada Seek Fresh Ranibizumab Partner In North America

Xbrane and Stada have announced that they are seeking a new North American partner for their biosimilar ranibizumab candidate after agreeing to discontinue a deal with Bausch+Lomb.

Biosimilars Deals

Stada Strikes Deal With Sanofi For Well-Established European Brands

Stada will strengthen its Consumer Healthcare business in key markets like Germany and the UK with the acquisition from Sanofi of an OTC brand portfolio including Opticrom eye drops and Omnivit vitamins.

Deals Strategy

Who’s Hired? Stada Names New Heads For UK And Eastern Europe

Stada has named new leaders for the UK and the Eastern Europe region. Meanwhile, French industry association Gemme has elected a fresh president and a new executive has joined Civica.

Executive Changes Leadership
See All

Company Information